Summary of PK studies thru 10/1/04* * Samples analyzed thru 5/30/04.

Slides:



Advertisements
Similar presentations
Paediatric HIV: update EACS Advanced HIV course Montpellier, 3-5 th Sept 2008 Carlo Giaquinto Department of Paediatrics, Padova, Italy.
Advertisements

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Paediatric Antiretroviral PK University of Liverpool, UK
Antiretroviral Treatment in the Context of TB/HIV Co-infection Major Aspects of Background Document 2 Marco Vitoria HIV/AIDS Department WHO Geneva Feb.
Group Work Recommendations-When to Start Group C.
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.
Starting children and infants on ART; what do the guidelines say? Dr Siobhan Crowley Paediatric & Family HIV Care Department of HIV/AIDS World Heath Organization,
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
Accomplishments Year 1 Encouraged HIV testing counseling with referrals to Phidisa 1 Education of Nursing Staff on Pediatric Wards Lectures to Medical.
Young person with multi-class resistance: follow-up and management (with perspectives from well-resourced and resource-limited settings) Gareth Tudor-Williams.
Hormonal Contraception: Special Considerations for HIV-infected Women Lori E. Kamemoto, MD, MPH Hawaii AIDS Clinical Research Program University of Hawaii.
Cohen_MDS218_final1 Second Regimens: Issues in Improving Success Calvin Cohen, MD, MS Clinical Instructor Harvard Medical School Research Director Community.
Roles of Protease Inhibitors for HIV-infected Children Jintanat Ananworanich.
Charge to the Committee Kimberly Struble, Pharm.D. Regulatory Review Officer Division of Antiviral Drug Products.
TB and HIV Dr Mohern Archary Paediatric Infectious Disease Specialist Dept of Paediatrics and Child Health, UKZN.
1 Management of anti retroviral treatment in patients with cirrhosis Dominique Salmon Cochin Hospital June 23, 2006.
KITSO AIDS Training Program
1 Pharmacokinetics and Drug Interactions HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Update on Atazanavir and the Early Access Program AIDS Treatment Activists Coalition Seattle, Washington February
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
5th International Workshop on Clinical Pharmacology of HIV Therapy – Rome 2004 Posters - L. Akagi.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinical Aspects of Treatment with Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures 24-Week Results.
Choice of Endpoints for Salvage Studies. Clinical Endpoints  AIDS-defining events  Survival  QOL  Marker-based Endpoints for Efficacy  HIV-1 RNA.
Highlights of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 14-17, 2003; Chicago, Illinois Selected and summarized.
1 Second Line ART: Doses & Side Effects HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Brett-Smith, ATAC, 2/24/02 Stavudine Extended Release (Zerit ® XR; d4T XR) Stavudine Prolonged Release Capsules ATAC Meeting 2/24/02.
WEEK 1 You have 10 seconds to name…
1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.
Second Line ARV: Doses & Side Effects HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Tenofovir (TFV), Emtricitabine (FTC), Intracellular Metabolite (TFV-dp, FTC-tp), and Endogenous Nucleotide (dATP, dCTP) Concentrations.
Antiretrovirals III: Pharmacokinetics and Drug Interactions
Design of the RESIST Study Program Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
Group Work Recommendations- what to start Group WHAT 1.
LDR 531 Week 3 Summary R-531/LDR-531-Week-3-Summary For more details
Genotype-directed dosing for Efavirenz
Optimizing Antiretorviral Therapy for Long-Term HIV Care
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
Visit for more Information: %284PK%29+-+New+Compatible+Inkjet+Cartridges.
HIV & TB Drug Interactions University of Liverpool
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
دستورالعمل پیشگیری از انتقال HIV از مادر به کودک
Gaps & obstacles Priorities & Solutions
Results of round 1 of the Delphi survey
Switch to E/C/F/TAF + DRV
Switch to LPV/r monotherapy
Forecasting for ARVs medicines
ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.
Comparison of NNRTI vs PI/r
Comparison of PI vs PI ATV vs ATV/r BMS 089
Antiretroviral therapy and its complications
C.2.10 Sample Questions.
C.2.8 Sample Questions.
C.2.8 Sample Questions.
Switch to LPV/r monotherapy
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Statistical Process Control
Drug levels during the course of a dosing interval.
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Figure 1. Rate of PDR in infants according to ARV exposure
Statistical Process Control
Electronic Document Room Biostat Reviewer Doses, Survival
Presentation transcript:

Summary of PK studies thru 10/1/04* * Samples analyzed thru 5/30/04

Immunosuppressant doses and Cmin after 2-4 weeks of rx

CsA Dosing by ARV and week CsA mg/dose NVPEFV1 PI2 PIkaletraNNRTI +PI NNRTI + kaletra Wk 2Wk 12Wk 28Yr 1Yr 2

Kaletra AUC by week pretx W2W12W28Y1Y2 efficacy LPVLPV + NNRTI LPV ng*h/mL RTVRTV + NNRTI RTV ng*h/mL

NFV NFV+NNRTI AUC ng*h/mL pretx W2W12W28Y1 efficacy NFV AUC by week M8/NFV AUC by week pretx21228yr 1yr 2 time AUC mcg*h/mL M8 NFV

NNRTI AUC by week NVP AUC ng*h/mL NVP NVP+ PI EFVEFV + PI EFV AUC ng*h/mL Wk 2 Wk 12Wk 28Yr 1Yr 2 pretx efficacy